1 / 30

Cardiac biomarkers in chronic kidney disease - 2

Cardiac biomarkers in chronic kidney disease - 2. Dr. Introduction. End-stage renal disease (ESRD) patients receiving renal replacement therapy have an excess of cardiovascular mortality Therefore, accurate diagnosis of acute cardiac syndromes in these patients is important.

micah
Download Presentation

Cardiac biomarkers in chronic kidney disease - 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Cardiac biomarkers in chronic kidney disease - 2 Dr.

  2. Introduction • End-stage renal disease (ESRD) patients receiving renal replacement therapy have an excess of cardiovascular mortality • Therefore, accurate diagnosis of acute cardiac syndromes in these patients is important Clinical Medicine & Research 2006; 4: 79-84

  3. Introduction • Available biochemical markers, especially those other than troponins, used to detect myocardial injury have been found to be falsely elevated in patients receiving maintenance dialysis Clinical Medicine & Research 2006; 4: 79-84

  4. Cardiac Enzymes • Troponins • The structural proteins of both cardiac and skeletal muscles and are responsible for regulation of actin-myosin binding • Cardiac troponins are specifically determined by monoclonal antibody assays since they are encoded by genes that are different from their skeletal counterparts Clinical Medicine & Research 2006; 4: 79-84

  5. Cardiac Enzymes • Troponin T, I, and C are three types of cardiac troponins that form the troponin complex • Both cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are very sensitive and specific markers of myocardial damage and are used widely for this aim • However, in the absence of a major, clinically evident cardiac injury, troponins are found to be elevated in several clinical conditions like ESRD, sepsis, pulmonary embolism and acute stroke • Creatine kinase myocardial isoform (CK-MB) is another marker commonly used for diagnosis of myocardial infarction Clinical Medicine & Research 2006; 4: 79-84

  6. ESRD and Cardiac Enzymes • Renal failure is one of the conditions in which serum markers of myocardial damage are falsely elevated • It is well known that levels of • Creatine kinase, • CK-MB and • Myoglobin are altered in patients with uremia Clinical Medicine & Research 2006; 4: 79-84

  7. ESRD and Cardiac Enzymes • In some studies it is demonstrated that elevated cardiac troponins are a sign of coronary artery disease when these patients were investigated invasively by angiography or non-invasively using stress cardiac isotopic imaging • However, there are reports showing that cardiac troponins, especially cTnT, might be elevated in patients with uremia without a clinically evident coronary ischemic event Clinical Medicine & Research 2006; 4: 79-84

  8. ESRD and Cardiac Enzymes • Angina • May be atypical or not observed due to silent ischemia and can be caused by factors other than coronary artery disease • In addition, • Nonspecific electrocardiogram findings are very common in these patients due to electrolyte imbalance, left ventricular hypertrophy and drug effects • Therefore, • The value of specific biochemical markers of myocardial injury is crucial to this patient population Clinical Medicine & Research 2006; 4: 79-84

  9. Acute myocardial infarction (MI) • In dialysis patients undergoing acute MI, • the time course of elevations in serum levels of • creatine kinase (CK), • aspartate aminotransferase (AST), and • lactate dehydrogenase (LDH) is presumably similar to that in nonuremic patients, • although no data to this effect have been published Daugirdas JT, Handbook of dialysis (2007) 4th ed.

  10. Acute myocardial infarction (MI) • It is of note that measurements of total CK and LDH are no longer recommended for the diagnosis of MI Daugirdas JT, Handbook of dialysis (2007) 4th ed.

  11. Acute myocardial infarction (MI) • A. Creatine kinase • Elevated baseline serum total CK level • Baseline s. total CK values are elevated persistently in 10-50% of dialysis patients • Elevation is usually mild (e.g <3 times ULN) • Occasionally 5-10 times ULN Daugirdas JT, Handbook of dialysis (2007) 4th ed. ULN – Upper limit of normal

  12. Acute myocardial infarction (MI) • A. Creatine kinase • Elevated baseline serum total CK level • Postulated causes of high levels • Intramuscular injection of androgens or other drugs • Subclinical myopathies, vitamin D deficiency • Carnitine deficiency, reduced degradation of enzyme Daugirdas JT, Handbook of dialysis (2007) 4th ed. ULN – Upper limit of normal

  13. Acute myocardial infarction (MI) • A. Creatine kinase • Elevated percentage of CK-MB • nonuremic patients upto 5% of total serum CK • 3 – 30% of dialysis patients without evidence of myocardial ischemia have been reported to have an elevated % of CK-MB • Recent studies report increase in ≤ 5% dialysis patients • When CK-MB % is increase in dialysis patients without MI, the elevation is slight • e.g. usually to <8% of the total CK value Daugirdas JT, Handbook of dialysis (2007) 4th ed. ULN – Upper limit of normal

  14. Acute myocardial infarction (MI) • A. Creatine kinase • Elevated percentage of CK-BB and CK – MM in acute renal failure • Serum levels of these isoenzymes are reportedly increased in patients with acute renal failure, • possibly due to their release from damaged renal tubular tissue • Stable hemodialysis patients, serum CK-BB concentration is usually in the normal range Daugirdas JT, Handbook of dialysis (2007) 4th ed. ULN – Upper limit of normal

  15. Acute myocardial infarction (MI) • B. Lactic dehydrogenase • Increase baseline serum LDH level • Serum levels of LDH may be elevated (to 3 times ULN) in as many as 35% of patients with renal insufficiency • Either due to reduced elimination rate or to increased release from damaged renal tissue in patients with acute renal failure Daugirdas JT, Handbook of dialysis (2007) 4th ed. ULN – Upper limit of normal

  16. Acute myocardial infarction (MI) • B. Lactic dehydrogenase • Human cardiac myosin light chain 1 • Enzyme immunoassay of cardiac myosin light chains has been proposed as a sensitive test for MI • Unfortunately in dialysis patients, serum levels of this compound are elevated 40-fold over control values • Accordingly, this test is not useful in the ESRD Daugirdas JT, Handbook of dialysis (2007) 4th ed. ULN – Upper limit of normal

  17. Acute myocardial infarction (MI) • C. Cardiac troponisns • Cardiac troponin T • Regulatory contractile protein – normally absent in blood, and its detection serves as a specific and sensitive indicator of myocardial damage • However, blood toponin T is elevated in over 80% of dialysis patients with no clinical evidence of acute myocardial injury Daugirdas JT, Handbook of dialysis (2007) 4th ed. ULN – Upper limit of normal

  18. ESRD and Cardiac Enzymes • Elevations in cardiac troponins in patients with ESRD result from a number of potential sources Clinical Medicine & Research 2006; 4: 79-84

  19. ESRD and Cardiac Enzymes • Cardiac toponin I • Another cardiac specific regulatory contractile protein, elevated blood levels of which are a specific indicator of cardiac injury • However, elevated troponin I levels occur in upto 8-9% of patients with advanced renal failure in the absence of clinical evidence of myocardial injury • Nonetheless, troponin I has been shown to be a • Reasonably accurate predictor of myocardial injury in renal failure patients and • More specific marker of acute MI than troponin T and CK-MB in this population • Hemodialysis does not significantly change the serum levels of troponin I Daugirdas JT, Handbook of dialysis (2007) 4th ed.

  20. ESRD and Cardiac Enzymes • As can be seen, there are many hypotheses, but the actual source of elevated cardiac troponins in the absence of a demonstrable myocardial injury in these patients is not clearly known • Myopathic skeletal muscle in patients with uremia seems to be one of the sources of falsely elevated levels of CK-MB • However, there is no clear reason for elevation of cTnI and cTnT without myocardial insult Clinical Medicine & Research 2006; 4: 79-84

  21. ESRD and Cardiac Enzymes • Data derived from the trials evaluating the diagnostic power of troponins in patients with ESRD for the diagnosis of myocardial damage vary widely • sensitivity for cTnT was reported to be as high as 100%* and in other studies, • specificity for cTnI was demonstrated to be as high as 100%,** while other trials showed • very low percentages of sensitivity and specificity for cardiac troponins • Available data, although not conclusive, suggest that • cTnI has higher specificity for cardiac injury in patients with ESRD *Clin Nephrol 2003;59:35-39, **Nephrol Dial Transplant 1998;13:1709-1712

  22. ESRD and Cardiac Enzymes • It has been suggested that chronically elevated troponin levels represent chronic structural cardiovascular disease such as • prior myocardial infarction, chronic CHF, or hypertension in the setting of chronic renal failure • These patients are at higher cardiac risk than the normal healthy patient population • Troponin is still a useful diagnostic marker in the setting of chronic renal failure

  23. ESRD and Cardiac Enzymes • Dialysis does not affect TnT or TnI levels • Predialysis and postdialysis levels are essentially unchanged • CK-MB, however, is dialyzable, • levels are decreased postdialysis • Therefore, • A single elevated TnT level in patients with chronic renal failure (CRF) and possible acute coronary syndrome (ACS) is nondiagnostic for AMI in the absence of other findings • The specificity of TnI is higher than TnT in this setting but not conclusive for AMI • Serial determinations are usually required, looking for a rise in the troponin level

  24. ESRD and Cardiac Enzymes • Therefore, ascertaining whether or not an elevated troponin in patients with chronic renal failure represents • true acute myocardial necrosis/infarction or a false-positive result can be difficult • In those patients with cardiac risk factors who are deemed clinically to be at moderate-high risk for ACS, the prudent approach would be • to observe and perform serial cardiac markers over 6-9 hours • In low-risk asymptomatic patients, • the clinician may decide that the elevated troponin result is false positive for AMI in the absence of any other findings indicative of ACS

  25. Cardiac enzymes: Prognostic significance • Elevated cardiac troponins in ESRD, the data are conflicting • In some studies, positive results of cTnT were found to have more prognostic importance, • In others cTnI were found to be more powerful for the prediction of future events • In some studies, combinations of them were shown to be good predictors of cardiovascular events, while some trials showed no prognostic value of positive troponin findings in the follow-up of these patients • But, when looking at the results of all these studies, • The prevalence of elevated levels of cTnT was more frequent and seems to have more prognostic value than cTnI Clinical Medicine & Research 2006; 4: 79-84

  26. Cardiac enzymes: Prognostic significance • The clinical significance of an elevated TnT level has been debated • The largest prospective studies have confirmed the association between TnT elevation and cardiac mortality • The GUSTO IV ACS trial revealed that patients with renal insufficiency and an elevated TnT had the highest overall risk of the composite endpoint of death or AMI • Two other prospective studies have reported that an elevated TnT but not TnI portended an increased long-term mortality risk • Whether the increased cardiac risk is in the short term (ie, 30 d) or only the long term is unclear • Patients without short-term risk may not require hospitalization and potentially could have workup completed on an outpatient basis

  27. Cardiac enzymes: Prognostic significance • An elevated cardiac troponin T more than 0.l mg/l is strongly associated with all cause mortality in haemodialyzed patients as shown in many trials • (McLaurin et al., 1997; Dierkes et al., 2000; Gabr et al., 2004) Journal of the Saudi Heart Association 2011:23, 3–11

  28. Cardiac enzymes: Prognostic significance • In renal failure elevated cardiac troponin is associated with a two- to five-fold increase in mortality but • reduced its sensitivity and specificity in suspected CAD (Apple et al., 2002; Goldmann et al., 2001; Van Lente et al., 1999). Journal of the Saudi Heart Association 2011:23, 3–11

  29. Conclusions • In light of the available data, we can conclude that • cTnI is more useful than cTnT and CK-MB for diagnosing myocardial injury

  30. Thank You!

More Related